source
- Novo files US and EU approval for etavopivat, its $1B acquired sickle-cell therapyNovo submitted regulatory applications in the United States and Europe for etavopivat, a sickle cell disease therapy it bought from Forma Therapeutics in a $1 billion transaction. The company says…
- CLINUVEL to cut up to 20% of staff and move headquarters to New YorkCLINUVEL announced a strategic reorganization aimed at focusing resources on the U.S. market. The company will reduce its global workforce by 10% to 20%, affecting up to 21 of its 104 employees.…